Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to optimize treatment strategies for patients with stage II and III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the quality of life.


Clinical Trial Description

The data came from conventional studies showed that the distant metastases and toxicities associated with concurrent chemoradiotherapy were main problems for patients with clinical stage II and III nasopharyngeal carcinoma. However, inductive chemotherapy can decrease the likelihood of emergence of distant metastasis and reduce treatment related toxicities as previous studies showed. The role of inductive chemotherapy in screening low-risk nasopharyngeal carcinoma for less treatment intensity is under-evaluated in the era of intensity-modulated radiotherapy (IMRT). we hope to find the optimized treatment strategies by reducing the intensity of treatment according to the treatment response of inductive chemotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03908372
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Junlin Yi, M.D
Phone 008601366121799
Email junlinyi@sohu.com
Status Recruiting
Phase Phase 2/Phase 3
Start date June 15, 2019
Completion date May 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05621707 - Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) Phase 2
Recruiting NCT01180166 - Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer Phase 2
Active, not recruiting NCT06342167 - Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT06288373 - Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Phase 2/Phase 3
Recruiting NCT03963882 - NAC Followed by RH for the Treatment of LACC Phase 2
Recruiting NCT05944809 - The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients Phase 2
Recruiting NCT03579004 - Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer Phase 2
Completed NCT02607982 - CCRT for Esophageal Cancer. Phase 2
Recruiting NCT06391190 - Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT06378840 - the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer